Table 2 Showing factors associated with willingness to participate in HIV Clinical Trials
Variable | Unadjusted OR (95% CI) | P-value | Adjusted OR (95% CI) | P-value |
|---|---|---|---|---|
Age | 0.98 (0.95–1.02) | 0.320 | 0.98 (0.94–1.03) | 0.531 |
Sex | ||||
Female | 1.00 | 1.00 | ||
Male | 1.56 (0.65–3.78) | 0.321 | 1.74 (0.52–5.84) | 0.372 |
Improved health status | ||||
Yes | 1.00 | 1.00 | ||
No | 0.12 (0.03–0.58) | 0.008 | 0.66 (0.04–12.44) | 0.784 |
CTs have a future benefit | ||||
Yes | 1.00 | 1.00 | ||
No | 0.39 (0.11–1.39) | 0.149 | 0.80 (0.10–6.56) | 0.833 |
Satisfactory compensation package | ||||
Yes | 1.00 | 1.00 | ||
No | 0.22 (0.08–0.56) | 0.002 | 0.27 (0.08–0.88) | 0.030 |
Patients are beneficiaries of CTs | ||||
Yes | 1.00 | 1.00 | ||
No | 0.45 (0.18–1.12) | 0.086 | 0.73 (0.22–2.44) | 0.606 |
CTs used in the development of new drugs | ||||
Yes | 1.00 | 1.00 | ||
No | 0.35 (0.12–1.05) | 0.061 | 5.52 (0.43–71.28) | 0.190 |
Special status accorded | ||||
Yes | 1.00 | 1.00 | ||
No | 0.13 (0.05–0.39) | < 0.001 | 0.11 (0.01–0.91) | 0.041 |
Side effects | ||||
Yes | 1.00 | 1.00 | ||
No | 0.20 (0.03–1.53) | 0.120 | 0.25 (0.03–2.23) | 0.215 |